The promise of epigenetics in personalized medicine

Molecular Interventions

Volumn 10, Issue 6, 2010, Pages 363-370

  Weber, Wendell W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; VORINOSTAT;

CHROMATIN IMMUNOPRECIPITATION; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC DISORDER; HISTONE MODIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; NEOPLASM; PROMOTER REGION; REVIEW; RISK ASSESSMENT;

DISEASE; DRUG THERAPY; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 79551493244     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.10.6.5     Document Type: Review

References (73)

1. Kornberg RD and Lorch Y (1999) Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98:285-294.
2. Luger K, Mader AW, Richmond RK, Sargent DF, and Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389:251-260.
3. Cheung P, Allis CD, and Sassone-Corsi P (2000) Signaling to chromatin through histone modifications. Cell 103:263-271.
4. Kornberg RD and Lorch Y (1999) Chromatin-modifying and -remodeling complexes. Curr Opin Genet Dev 9:148-151.
5. Saha A, Wittmeyer J, and Cairns BR (2006) Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 7:437-447.
6. Holliday R (2006) Epigenetics: a historical overview. Epigenetics 1:76-80.
7. Bird A (2007) Perceptions of epigenetics. Nature 447:396-398.
8. Portela A and Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28:1057-1068.
9. Johnstone SE and Baylin SB (2010) Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat Rev Genet 11:806-812.
10. Halfmann R and Lindquist S (2010) Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science 330:629-632.
11. Gomez A and Ingelman-Sundberg M (2009) Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 85:426-430.
12. Gomez A and Ingelman-Sundberg M (2009) Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. Pharmacogenomics 10:1067-1076.
13. Brockmoller J and Tzvetkov MV (2008). Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 64:133-157.
14. Hanson MA and Gluckman PD (2008) Developmental origins of health and disease: new insights. Basic Clin Pharmacol Toxicol 102:90-93.
15. Fan S and Zhang X (2009) CpG island methylation pattern in different human tissues and its correlation with gene expression. Biochem Biophys Res Commun 383:421-425.
16. Murrell A, Rakyan VK, and Beck S (2005) From genome to epigenome. Hum Mol Genet 14 Spec No 1:R3-R10.
17. Gilbert SF (2009) Ageing and cancer as diseases of epigenesis. J Biosci 34:601-604.
18. Dolinoy DC, Huang D, and Jirtle RL (2007) Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci USA 104:13056-13061.
19. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P (2006) Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8:46-51.
20. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, et al. (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3:1709-1723.
21. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, and Kelsey KT (2001) p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61:3419-3424.
22. Tessema M, Willink R, Do K, Yu YY, Yu W, Machida EO, Brock M, Van Neste L, Stidley CA, Baylin SB (2008) Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res 68:1707-1714.
23. Duthie SJ (2010) Epigenetic modifications and human pathologies: cancer and CVD. Proc Nutr Soc 11:1-10.
24. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, Slagboom PE, and Lumey LH (2008) Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA 105:17046-17049.
25. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261-282.
26. Cooper DN and Youssoufian H (1998) The CpG dinucleotide and human genetic disease. Hum Genet 78:151-155.
27. Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
28. Bird AP and Taggart MH (1980) Variable patterns of total DNA and rDNA methylation in animals. Nucleic Acids Res 8:1485-97.
29. Bird AP (1993) Functions for DNA methylation in vertebrates. Cold Spring Harb Symp Quant Biol 58:281-285.
30. Yoder JA, Walsh CP, and Bestor TH (1997) Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13:335-340.
31. Cross SH and Bird AP (1995) CpG islands and genes. Curr Opin Genet Dev 5:309-314.
32. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, and Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389.
33. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, and Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187-191.
34. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D, and Bird A (1999) MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23:58-61.
35. Tamaru H and Selker EU (2001) A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414:277-283.
36. Nakayama J, Rice JC, Strahl BD, Allis CD, and Grewal SI (2001) Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292:110-113.
37. Bestor TH (1998) Gene silencing. Methylation meets acetylation. Nature 393:311-312.
38. Edwards JR, O'Donnell AH, Rollins RA, Peckham HE, Lee C, Milekic MH, Chanrion B, Fu Y, Su T, Hibshoosh H, et al. (2010) Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res 20:972-980.
39. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705.
40. Cosgrove MS and Wolberger C (2005) How does the histone code work? Biochem Cell Biol 83:468-476.
41. Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403:41-45.
42. Spannhoff A, Hauser AT, Heinke R, Sippl W, and Jung M (2009) The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 4:1568-1582.
43. Lillycrop KA and Burdge GC (2010) Epigenetic changes in early life and future risk of obesity. Int J Obes (Lond) doi:10.1038/ijo.2010.122.
44. Cox GF, Burger J, Lip V, Mau UA, Sperling K, Wu BL, and Horsthemke B (2002) Intracytoplasmic sperm injection may increase the risk of imprinting defects. Am J Hum Genet 71:162-164.
45. DeBaun MR, Niemitz EL, and Feinberg AP (2003) Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 72:156-160.
46. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148-1159.
47. Feinberg AP and Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92.
48. Feinberg AP, Gehrke CW, Kuo KC, and Ehrlich M (1988) Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 48:1159-1161.
49. Baylin SB, Hoppener JW, de Bustros A, Steenbergh PH, Lips CJ, and Nelkin BD (1986) DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 46:2917-2922.
50. Esteller M, Corn PG, Baylin SB, and Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229.
51. Jacinto FV and Esteller M (2007) Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22:247-253.
52. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
53. Cheung HH, Lee TL, Rennert OM, and Chan WY (2009) DNA methylation of cancer genome. Birth Defects Res C Embryo Today 87:335-350.
54. McCabe MT, Brandes JC, and Vertino PM (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15:3927-3937.
55. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178-186.
56. Miremadi A, Oestergard MZ, Pharaoh PD, and Caldas C (2007) Cancer genetics of epigenetic genes. Hum Mol Gen 16:R28-R49.
57. Ellis L, Atadja PW, and Johnstone RW (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8:1409-1420.
58. Jones PA and Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692.
59. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400.
60. Egger G, Liang G, Aparicio A, and Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463.
61. Gilbert J, Gore SD, Herman JG, and Carducci MA (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-4596.
62. Karberg S (2009) Switching on epigenetic therapy. Cell 139:1029-1031.
63. Friedrich MJ (2010) Epigenetic therapies offer new approach to fighting cancer at the genetic level. JAMA 303:213-214.
64. Spannhoff A, Sippl W, and Jung M (2009) Cancer treatment of the future: inhibitors of histone methyltransferases. Int J Biochem Cell Biol 41:4-11.
65. Breslow R (2009) Vorinostat. Mol. Interv. 9:114-115.
66. Yoo CB and Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37-50.
67. Dutnall RN and Denu JM (2002) Methyl magic and HAT tricks. Nat Struct Biol 9:888-991.
68. Richly H, Lange M, Simboeck E, and Di Croce L (2010) Setting and resetting of epigenetic marks in malignant transformation and development. BioEssays 32:669-679.
69. Slack JM (2002) Conrad Hal Waddington: the last Renaissance biologist? Nat Rev Genet 3:889-895.
70. Look AT (1997) Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
71. Schones DE and Zhao K (2008) Genome-wide approaches to studying chromatin modifications. Nat Rev Genet 9:179-191.
72. Callinan PA and Feinberg AP (2006) The emerging science of epigenomics. Hum Mol Genet 15 Spec No 1:R95-R101.
73. Jones PA (2010) The AACR Human Epigenome Task Force and EUNE SAB. Moving AHEAD with an international human epigenome project. Nature 454:711-715.